NEW YORK (GenomeWeb) – While most investors' eyes are on the adoption of NanoString Technologies' ProSigna Breast Cancer Gene Signature Assay, the firm's business with researchers continues to thrive.

Instrument and consumables sales drove the Seattle-based company's second quarter revenues up 51 percent, with 80 percent of the company's new nCounter system placements related to oncology research and diagnostics, the firm reported last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.